Perioperative medicine & outcomes
Novel Cancer Therapeutics: Perioperative Implications and Challenges
Study context
- Population
- Patients receiving novel cancer therapies (checkpoint inhibitors and targeted therapies) in the perioperative setting
Main finding
As reported in the abstract
- Toxicity profile of immunotherapy and targeted therapies is broad, can have an insidious onset, and recognition can be challenging
- Rarely, toxicities can cause significant morbidity if not diagnosed early and lead to intensive care unit (ICU) admission and death
- Anesthesiologists may be first to make the diagnosis and need to rapidly assess, establish differentials, perform a diagnostic workup, and evaluate perioperative impact
Original publication
Novel Cancer Therapeutics: Perioperative Implications and Challenges. Anesth Analg. Published 25 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →